← Leaderboards
Wen-Cheng Xiong
Louis Stokes Cleveland Va Medical Center
$16,782,331
Attributed
$20,177,042
Total exposure
15
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,177,042 · 13
VA$0 · 2
By mechanism
R01$11,930,170 · 8
RF1$7,446,872 · 3
R56$800,000 · 1
I01$0 · 2
P30$0 · 1
Top collaborators
- Richard E Zigmond4 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposMutantSignal TransductionMutationPathogenesisCellsDementiaS DiseasePathologicFamilyProteinsAmyloid Beta-Protein PrecursorLinkGenesBrainTg2576MolecularReceptorIn VivoOsteoclastsSelective ExpressionMediatingOsteoporosisImpairment
Grant awards (57)
Skeletal Muscular Swedish Mutant APP in Alzheimer's Disease Development$0
I01 · FY2025 · VA · contact PI
LRP4 deficiency in Alzheimer's disease development$707,854
R01 · FY2024 · AG · contact PI
Swedish APP mutation and NMJ decline in Alzheimer's disease$643,654
R01 · FY2024 · AG · contact PI
Skeletal Muscular Swedish Mutant APP in Alzheimer's Disease Development$0
I01 · FY2024 · VA · contact PI
Skeletal Muscular Swedish Mutant APP in Alzheimer's Disease Development$0
I01 · FY2023 · VA · contact PI
Mechanisms of neuromuscular junction formation$564,117
R01 · FY2022 · NS · contact PI
Skeletal Muscular Swedish Mutant APP in Alzheimer's Disease Development$0
I01 · FY2022 · VA · contact PI
Mechanisms of neuromuscular junction formation$568,681
R01 · FY2021 · NS · contact PI
APPswe as a risk factor for osteoporosis$0
I01 · FY2021 · VA · contact PI
LRP4 deficiency in Alzheimer's disease development$2,846,666
RF1 · FY2020 · AG · contact PI
Swedish APP mutation and NMJ decline in Alzheimer's disease$2,591,248
RF1 · FY2020 · AG · contact PI
Mechanisms of neuromuscular junction formation$581,257
R01 · FY2020 · NS · contact PI
APP as a common denominator for Alzheimer's disease and osteoporosis$400,000
R01 · FY2020 · AG · contact PI
APPswe as a risk factor for osteoporosis$0
I01 · FY2020 · VA · contact PI
Retromer deficiency and Alzheimer's disease pathology$2,008,958
RF1 · FY2019 · AG · contact PI
APP as a common denominator for Alzheimer's disease and osteoporosis$400,000
R01 · FY2019 · AG · contact PI
Contributions of osteoblastic and muscular APPswe to the pathogenesis of Alzheimers disease$400,000
R56 · FY2019 · AG · contact PI
APPswe as a risk factor for osteoporosis$0
I01 · FY2019 · VA · contact PI
Contributions of osteoblastic and muscular APPswe to the pathogenesis of Alzheimers disease$400,000
R56 · FY2018 · AG · contact PI
APP as a common denominator for Alzheimer's disease and osteoporosis$400,000
R01 · FY2018 · AG · contact PI
APPswe as a risk factor for osteoporosis$0
I01 · FY2018 · VA · contact PI
Retromer deficiency and Alzheimer's disease pathology$328,000
R01 · FY2017 · AG · contact PI
Retromer deficiency and Alzheimer's disease pathology$311,600
R01 · FY2017 · AG · contact PI
APP as a common denominator for Alzheimer's disease and osteoporosis$286,084
R01 · FY2017 · AG · contact PI
Retromer deficiency and Alzheimer's disease pathology$133,921
R01 · FY2017 · AG · contact PI
APP as a common denominator for Alzheimer's disease and osteoporosis$93,916
R01 · FY2017 · AG · contact PI
APPswe as a risk factor for osteoporosis$0
I01 · FY2017 · VA · contact PI
APP as a common denominator for Alzheimer's disease and osteoporosis$380,000
R01 · FY2016 · AG · contact PI
Retromer deficiency and Alzheimer's disease pathology$311,600
R01 · FY2016 · AG · contact PI
Retromer deficiency and Alzheimer's disease pathology$301,920
R01 · FY2015 · AG · contact PI
Amyloid-RAGE Signaling in Bone Remodeling$0
I01 · FY2015 · VA · contact PI
Retromer deficiency and Alzheimer's disease pathology$309,209
R01 · FY2014 · AG · contact PI
Amyloid-RAGE Signaling in Bone Remodeling$0
I01 · FY2014 · VA · contact PI
Amyloid-RAGE Signaling in Bone Remodeling$0
I01 · FY2013 · VA · contact PI
Molecular Mechanisms Underlying Axon Pathfinding$315,131
R01 · FY2012 · NS · contact PI
Molecular Mechanisms Underlying Axon Pathfinding$315,131
R01 · FY2011 · NS · contact PI
MOLECULAR MECHANISMS UNDERLYING OSTEOCLAST ACTIVATION$294,366
R01 · FY2011 · AR · contact PI
Amyloid-RAGE Signaling in Bone Remodeling$0
I01 · FY2011 · VA · contact PI
Molecular Mechanisms Underlying Axon Pathfinding$318,348
R01 · FY2010 · NS · contact PI
MOLECULAR MECHANISMS UNDERLYING OSTEOCLAST ACTIVATION$306,632
R01 · FY2010 · AR · contact PI
Molecular Mechanisms Underlying Axon Pathfinding$321,563
R01 · FY2009 · NS · contact PI
MOLECULAR MECHANISMS UNDERLYING OSTEOCLAST ACTIVATION$309,729
R01 · FY2009 · AR · contact PI
Molecular Mechanisms Underlying Axon Pathfinding$321,563
R01 · FY2008 · NS · contact PI
MOLECULAR MECHANISMS UNDERLYING OSTEOCLAST ACTIVATION$309,729
R01 · FY2008 · AR · contact PI
MOLECULAR MECHANISMS UNDERLYING OSTEOCLAST ACTIVATION$316,050
R01 · FY2007 · AR · contact PI
FAK family tyrosine kinases and Rho family GTPases$230,406
R01 · FY2006 · GM · contact PI
FAK family tyrosine kinases and Rho family GTPases$235,950
R01 · FY2005 · GM
ROLE OF PYK2 IN REGULATING OSTEOCLASTIC BONE RESORPTION$205,205
R01 · FY2005 · AR
ROLE OF PYK2 IN REGULATING OSTEOCLASTIC BONE RESORPTION$235,235
R01 · FY2004 · AR
FAK family tyrosine kinases and Rho family GTPases$180,753
R01 · FY2004 · GM
FAK family tyrosine kinases and Rho family GTPases$38,250
R01 · FY2004 · GM
FAK family tyrosine kinases and Rho family GTPases$239,250
R01 · FY2003 · GM
ROLE OF PYK2 IN REGULATING OSTEOCLASTIC BONE RESORPTION$238,525
R01 · FY2003 · AR
FAK family tyrosine kinases and Rho family GTPases$238,838
R01 · FY2002 · GM
ROLE OF PYK2 IN REGULATING OSTEOCLASTIC BONE RESORPTION$237,703
R01 · FY2002 · AR
Pilot--PYK2 and FAK in osteoclastic bone resorption$0
P30 · FY2002 · AR
Pilot--PYK2 and FAK in osteoclastic bone resorption$0
P30 · FY2001 · AR